Nnorom Chukwuma C, Davis Corinne, Fedinec Alexander L, Howell Khadesia, Jaggar Jonathan H, Parfenova Helena, Pourcyrous Massroor, Leffler Charles W
Departments of Physiology and Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee.
Physiol Rep. 2014 Aug 28;2(8). doi: 10.14814/phy2.12127. Print 2014 Aug 1.
Mechanisms by which Pco2 controls cerebral vascular tone remain uncertain. We hypothesize that potassium channel activation contributes to the neonatal cerebrovascular dilation in response to increases in Paco2. To test this hypothesis, experiments were performed on newborn pigs with surgically implanted, closed cranial windows. Hypercapnia was induced by ventilation with elevated Pco2 gas in the absence and presence of the KATP channel inhibitor, glibenclamide and/or the KCa channel inhibitor, paxillin. Dilations to pinacidil, a selective KATP channel activator, without and with glibenclamide, were used to evaluate the efficacy of KATP channel inhibition. Dilations to NS1619, a selective KCa channel activator, without and with paxillin, were used to evaluate the efficacy of KCa channel inhibition. Cerebrovascular responses to the KATP and KCa channel activators, pinacidil and NS1619, respectively, cAMP-dependent dilator, isoproterenol, and cGMP-dependent dilator, sodium nitroprusside (SNP), were used to evaluate the selectivity of glibenclamide and paxillin. Glibenclamide blocked dilation to pinacidil, but did not inhibit dilations to NS1619, isoproterenol, or SNP. Glibenclamide prior to hypercapnia decreased mean pial arteriole dilation ~60%. Glibenclamide treatment during hypercapnia constricted arterioles ~35%. The level of hypercapnia, Paco2 between 50 and 75 mmHg, did not appear to be involved in efficacy of glibenclamide in blocking dilation to Paco2. Similarly to glibenclamide and KATP channel inhibition, paxillin blocked dilation to the KCa channel agonist, NS1619, and attenuated, but did not block, arteriolar dilation to hypercapnia. Treatment with both glibenclamide and paxillin abolished dilation to hypercapnia. Therefore, either glibenclamide or paxillin that block dilation to their channel agonists, pinacidil or NS1619, respectively, only partially inhibit dilation to hypercapnia. Block of both KATP and KCa channels completely prevent dilation hypercapnia. These data suggest hypercapnia activates both KATP and KCa channels leading to cerebral arteriolar dilation in newborn pigs.
二氧化碳分压(Pco2)控制脑血管张力的机制仍不明确。我们假设钾通道激活有助于新生儿脑血管在动脉血二氧化碳分压(Paco2)升高时发生扩张。为验证这一假设,我们对手术植入闭合式颅窗的新生猪进行了实验。在不存在和存在KATP通道抑制剂格列本脲和/或钾钙通道(KCa)抑制剂帕西illin的情况下,通过用高Pco2气体通气诱导高碳酸血症。使用对匹那地尔(一种选择性KATP通道激活剂)在不存在和存在格列本脲时的扩张反应来评估KATP通道抑制的效果。使用对NS1619(一种选择性KCa通道激活剂)在不存在和存在帕西illin时的扩张反应来评估KCa通道抑制的效果。分别使用脑血管对KATP和KCa通道激活剂匹那地尔和NS1619、环磷酸腺苷(cAMP)依赖性扩张剂异丙肾上腺素以及环磷酸鸟苷(cGMP)依赖性扩张剂硝普钠(SNP)的反应来评估格列本脲和帕西illin的选择性。格列本脲阻断了对匹那地尔的扩张反应,但不抑制对NS1619、异丙肾上腺素或SNP的扩张反应。在高碳酸血症之前给予格列本脲可使软脑膜小动脉平均扩张减少约60%。在高碳酸血症期间给予格列本脲治疗可使小动脉收缩约35%。高碳酸血症水平(Paco2在50至75 mmHg之间)似乎与格列本脲阻断对Paco2的扩张反应的效果无关。与格列本脲和KATP通道抑制情况类似,帕西illin阻断了对KCa通道激动剂NS1619的扩张反应,并减弱但未阻断小动脉对高碳酸血症的扩张反应。同时使用格列本脲和帕西illin治疗可消除对高碳酸血症的扩张反应。因此,分别阻断对其通道激动剂匹那地尔或NS1619扩张反应的格列本脲或帕西illin仅部分抑制对高碳酸血症的扩张反应。阻断KATP和KCa通道均可完全阻止对高碳酸血症的扩张反应。这些数据表明,高碳酸血症激活KATP和KCa通道,导致新生猪脑小动脉扩张。